ArticleNucleic acids research2015
Evaluating the potential for undesired genomic effects of the piggyBac transposon system in human cells.
Article in Nucleic acids research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05054257 (Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor-modified Autologous T Cells), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor-modified Autologous T Cells (CART19) in Patients with Relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma. a Dose Escalation, Open-label, Phase I Study.
Who cites it
27 citing papers in PubMed, 52 citations in OpenAlex.
- Advances in Induced Pluripotent Stem Cell Reprogramming and Its Application in Amyotrophic Lateral Sclerosis: A Review.FASEB bioAdvances · 2025Review
- Current Non-Viral-Based Strategies to Manufacture CAR-T Cells.International journal of molecular sciences · 2024Review
- Stargardt macular dystrophy and therapeutic approaches.The British journal of ophthalmology · 2024Review
- Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges.Frontiers in immunology · 2024Review
- Response to: DNA transposon mechanisms and pathways of genotoxicity.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- DNA transposon mechanisms and pathways of genotoxicity.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- ASIS-Seq: Transgene Insertion Site Mapping by Nanopore Adaptive Sampling.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Article
- Transposase-CRISPR mediated targeted integration (TransCRISTI) in the human genome.Scientific reports · 2022Article
- Progress of Transposon Vector System for Production of Recombinant Therapeutic Proteins in Mammalian Cells.Frontiers in bioengineering and biotechnology · 2022Review
- Non-codon Optimized PiggyBac Transposase Induces Developmental Brain Aberrations: A Call forFrontiers in cell and developmental biology · 2021Article
- Applications ofStem cells international · 2021Review
- Genome Engineering of Yarrowia lipolytica with the PiggyBac Transposon System.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Genome Engineering Renal Epithelial Cells for Enhanced Volume Transport Function.Cellular and molecular bioengineering · 2020Article
- Cellular and metabolic engineering of oleaginous yeastEngineering in life sciences · 2019Review
- A piggyBac-based TANGO GFP assay for high throughput screening of GPCR ligands in live cells.Cell communication and signaling : CCS · 2019Article
- PiggyBac transposon system with polymeric gene carrier transfected into human T cells.American journal of translational research · 2019Article
- Time-Restricted PiggyBac DNA Transposition by Transposase Protein Delivery Using Lentivirus-Derived Nanoparticles.Molecular therapy. Nucleic acids · 2018Article
- Long-term health and germline transmission in transgenic cattle following transposon-mediated gene transfer.BMC genomics · 2018Article
- Bioengineering Solutions for Manufacturing Challenges in CAR T Cells.Biotechnology journal · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Non-viral transposons have been used successfully for genetic modification of clinically relevant cells including embryonic stem, induced pluripotent stem, hematopoietic stem and primary human T cell types. However, there has been limited evaluation of undesired genomic effects when using transposons for human genome modification. The prevalence of piggyBac(PB)-like terminal repeat (TR) elements in the human genome raises concerns. We evaluated if there were undesired genomic effects of the PB transposon system to modify human cells. Expression of the transposase alone revealed no mobilization of endogenous PB-like sequences in the human genome and no increase in DNA double-strand breaks. The use of PB in a plasmid containing both transposase and transposon greatly increased the probability of transposase integration; however, using transposon and transposase from separate vectors circumvented this. Placing a eGFP transgene within transposon vector backbone allowed isolation of cells free from vector backbone DNA. We confirmed observable directional promoter activity within the 5'TR element of PB but found no significant enhancer effects from the transposon DNA sequence. Long-term culture of primary human cells modified with eGFP-transposons revealed no selective growth advantage of transposon-harboring cells. PB represents a promising vector system for genetic modification of human cells with limited undesired genomic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.